860 related articles for article (PubMed ID: 18337603)
1. VEGF inhibition and renal thrombotic microangiopathy.
Eremina V; Jefferson JA; Kowalewska J; Hochster H; Haas M; Weisstuch J; Richardson C; Kopp JB; Kabir MG; Backx PH; Gerber HP; Ferrara N; Barisoni L; Alpers CE; Quaggin SE
N Engl J Med; 2008 Mar; 358(11):1129-36. PubMed ID: 18337603
[TBL] [Abstract][Full Text] [Related]
2. VEGF inhibition and renal thrombotic microangiopathy.
Nochy D; Lefaucheur C; Hill G
N Engl J Med; 2008 Jul; 359(2):206; author reply 206-7. PubMed ID: 18618951
[No Abstract] [Full Text] [Related]
3. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
5. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
Frangié C; Lefaucheur C; Medioni J; Jacquot C; Hill GS; Nochy D
Lancet Oncol; 2007 Feb; 8(2):177-8. PubMed ID: 17267332
[No Abstract] [Full Text] [Related]
6. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
[TBL] [Abstract][Full Text] [Related]
7. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.
Roncone D; Satoskar A; Nadasdy T; Monk JP; Rovin BH
Nat Clin Pract Nephrol; 2007 May; 3(5):287-93. PubMed ID: 17457362
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy.
Suga S; Kim YG; Joly A; Puchacz E; Kang DH; Jefferson JA; Abraham JA; Hughes J; Johnson RJ; Schreiner GF
Kidney Int; 2001 Oct; 60(4):1297-308. PubMed ID: 11576344
[TBL] [Abstract][Full Text] [Related]
9. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
Eremina V; Quaggin SE
Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab-associated glomerular microangiopathy.
Person F; Rinschen MM; Brix SR; Wulf S; Noriega MLM; Fehrle W; Schmitz J; Schwarz A; Ivanyi P; Steinmetz OM; Reinhard L; Hoxha E; Zipfel PF; Bräsen JH; Wiech T
Mod Pathol; 2019 May; 32(5):684-700. PubMed ID: 30552416
[TBL] [Abstract][Full Text] [Related]
11. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
[TBL] [Abstract][Full Text] [Related]
12. VEGF inhibition and renal thrombotic microangiopathy.
Katavetin P; Katavetin P
N Engl J Med; 2008 Jul; 359(2):205-6; author reply 206-7. PubMed ID: 18614790
[No Abstract] [Full Text] [Related]
13. Renal involvement in preeclampsia: similarities to VEGF ablation therapy.
Müller-Deile J; Schiffer M
J Pregnancy; 2011; 2011():176973. PubMed ID: 21494322
[TBL] [Abstract][Full Text] [Related]
14. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists.
Zhang PL; Raza S; Li W; Kanaan HD
Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042
[TBL] [Abstract][Full Text] [Related]
15. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
Keller K; Daniel C; Schöcklmann H; Endlich KH; Kerjaschki D; Johnson RJ; Hugo C
Nephrol Dial Transplant; 2006 Oct; 21(10):2724-35. PubMed ID: 16861242
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature.
Yahata M; Nakaya I; Sakuma T; Sato H; Aoki S; Soma J
BMC Res Notes; 2013 Nov; 6():450. PubMed ID: 24207130
[TBL] [Abstract][Full Text] [Related]
17. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review.
Nagayama Y; Yamano M; Yagame M; Nariyama T; Takahashi M; Kawamoto M; Matsui K
BMC Nephrol; 2019 Oct; 20(1):375. PubMed ID: 31623576
[TBL] [Abstract][Full Text] [Related]
18. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
[TBL] [Abstract][Full Text] [Related]
19. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M
Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486
[TBL] [Abstract][Full Text] [Related]
20. Vegfa protects the glomerular microvasculature in diabetes.
Sivaskandarajah GA; Jeansson M; Maezawa Y; Eremina V; Baelde HJ; Quaggin SE
Diabetes; 2012 Nov; 61(11):2958-66. PubMed ID: 23093658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
